Vyteris, Inc. is realigning the company in an effort to become a diversified specialty CRO. This decision follows on the company’s merger with CRO, MediSync BioServices, Inc. Vyteris will now focus all its efforts on consolidating specialty businesses in the CRO, site management organization (SMO) and related services industry. The company is discontinuing its drug delivery business and plans to sell its active transdermal drug-delivery assets.

Vyteris aims to bring together established and profitable privately held CROs, SMOs and related consulting firms to build a cluster of businesses with complementary specialized services and is pursuing multiple acquisition targets expected to close in 2011 and 2012.

“We are excited to be transforming Vyteris into a leading niche player in the specialty CRO industry by executing our strategy for consolidation, growth and potential profitability in an established industry with exciting growth potential,” said Haro Hartounian, Ph.D., chief executive officer at Vyteris. “Our plan is to acquire small, private CROs with successful track records that lack the capital raising power, business development resources and scale to compete with large CROs. With our entrepreneurial leadership and industry experience, we are confident this strategy will provide Vyteris and its shareholders a significant growth opportunity and value proposition.”